All In Biotech

NDA 204251 · Alcon Labs INC

Simbrinza

Brimonidine Tartrate, Brinzolamide · Ophthalmic · Carbonic Anhydrase Inhibitor

Last checked: Nov 20, 2026Latest source record: May 5, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Apr 19, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

177

44 Phase 3, 5 recruiting

FAERS reports

4,182

1,782 serious, 150 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2025.

SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. SIMBRINZA is a combination of brinzolamide, a carbonic anhydrase inhibitor, and brimonidine tartrate, an alpha adrenergic agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (1)

Mechanism: SIMBRINZA is comprised of two components: brinzolamide (carbonic anhydrase inhibitor) and brimonidine tartrate (alpha 2 adrenergic receptor agonist). Each of these two components decreases elevated IOP. Elevated IOP is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of IOP, the greater the likelihood of glaucomatous field loss and optic nerve damage. Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SIMBRINZA · BRIMONIDINE TARTRATE 0.2%; BRINZOLAMIDE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.

All 177 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure382
  • ocular hyperaemia366
  • drug ineffective354
  • eye irritation353
  • vision blurred259
  • eye pain237
  • dizziness204
  • hypersensitivity198
  • intraocular pressure increased186
  • visual impairment180
  • fatigue174
  • glaucoma157

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
201315
201451
2015156
2016367
2017507
2018547
2019487
2020753
2021333
2022190
2023193
2024218
2025213
2026151

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Simbrinza (Brinzolamide/Brimonidine Tart)

2024 spending

$78.9M

Beneficiaries

74,537

301,984 claims

Per beneficiary

$1,058

$25.05 per unit

View as table
YearSpending
2020$69,369,481
2021$64,748,025
2022$67,796,894
2023$75,557,279
2024$78,872,651

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 312 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.